uOttawa Department of Psychiatry, Ottawa, ON, Canada (Sinthuja S, KP); Department of Applied Psychology and Human Development, University of Toronto, Toronto, ON, Canada (DJ); Columbia University Mailman School of Public Health, Department of Epidemiology, New York, NY (Shalini S); uOttawa School of Epidemiology and Public Health, Ottawa, ON, Canada (FLT); Department of Neuroscience, Carleton University, Ottawa, ON, Canada (SDS, PP); CHEO Research Institute, Ottawa, ON, Canada (MS, KP).
J Addict Med. 2022;16(1):101-109. doi: 10.1097/ADM.0000000000000818.
Child and adolescent psychiatric (CAP) inpatient admissions have increased since 2009 and the clinical profile of these patients has become more complex. Unrecognized dual diagnosis, that is, comorbid substance use or substance use disorder (SUD) may contribute to this problem, but the prevalence of dual diagnosis in this population is inadequately understood. The goal of this scoping review was to summarize the range and content of research on this topic.
MEDLINE, EMBASE, and PsychINFO databases were systematically searched for studies published from 2008 to 2019 containing information on rates of comorbid substance use or SUD in CAP inpatients.
A total of 23,326 abstracts were located. After removing duplicates, screening abstracts and full-text papers, and extracting data with full-text reviews, fourteen studies meeting our criteria remained. Rates of substance use or SUD ranged from 0.9% to 54.8%, differing on the basis of: (1) type of outcome; (2) type of data source; and (3) whether samples had a specific diagnostic focus or not. Rates of any type of SUD were reported in approximately 25% of samples from administrative databases, in 17.7% to 38.5% of chart reviews, and in 55% of studies with data from clinical research examinations. The highest rates of substance-specific substance use or SUD were for alcohol, cannabis, and nicotine.
We located 14 studies, but methodologic heterogeneity precluded quantitative calculation of a single estimate for the prevalence of dual diagnosis. However, most of the rates suggest that this is an important problem in CAP inpatients, meriting further research. We suggest ways to improve future studies.
自 2009 年以来,儿童和青少年精神病学(CAP)住院患者人数有所增加,且这些患者的临床特征变得更加复杂。未被识别的双重诊断,即合并物质使用或物质使用障碍(SUD),可能是造成这一问题的原因之一,但该人群中双重诊断的患病率尚未得到充分了解。本综述的目的是总结该主题的研究范围和内容。
系统检索了 MEDLINE、EMBASE 和 PsychINFO 数据库,以查找 2008 年至 2019 年期间发表的包含 CAP 住院患者合并物质使用或 SUD 发生率信息的研究。
共定位了 23,326 篇摘要。在去除重复项、筛选摘要和全文论文以及使用全文审查提取数据之后,符合我们标准的研究仍有 14 项。物质使用或 SUD 的发生率从 0.9%到 54.8%不等,差异在于:(1)结果类型;(2)数据源类型;(3)样本是否具有特定的诊断重点。在来自行政数据库的样本中,约有 25%报告了任何类型的 SUD 率,在病历回顾中为 17.7%至 38.5%,在临床研究检查中数据的研究中为 55%。物质特异性物质使用或 SUD 的最高发生率是酒精、大麻和尼古丁。
我们找到了 14 项研究,但方法学的异质性使得无法对双重诊断的患病率进行单一估计的定量计算。然而,大多数研究表明,这是 CAP 住院患者中的一个重要问题,值得进一步研究。我们提出了改进未来研究的方法。